State of Wisconsin Investment Board purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,000 shares of the biotechnology company’s stock, valued at approximately $132,000. State of Wisconsin Investment Board owned approximately 0.06% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Rhumbline Advisers bought a new position in Pieris Pharmaceuticals in the 2nd quarter valued at about $184,000. Schwab Charles Investment Management Inc. bought a new position in Pieris Pharmaceuticals in the 2nd quarter valued at about $292,000. Acadian Asset Management LLC bought a new position in Pieris Pharmaceuticals in the 2nd quarter valued at about $162,000. Creative Planning lifted its position in Pieris Pharmaceuticals by 8.3% in the 2nd quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pieris Pharmaceuticals in the 1st quarter valued at about $661,000. 50.55% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages recently weighed in on PIRS. HC Wainwright set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Rodman & Renshaw began coverage on shares of Pieris Pharmaceuticals in a research report on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, TheStreet cut shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. Five investment analysts have rated the stock with a buy rating, Pieris Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $8.25.

In other Pieris Pharmaceuticals news, insider Allan Reine acquired 65,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, with a total value of $313,300.00. Following the completion of the purchase, the insider now directly owns 45,000 shares of the company’s stock, valued at approximately $216,900. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James A. Geraghty acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average cost of $4.82 per share, for a total transaction of $48,200.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $48,200. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.

Pieris Pharmaceuticals, Inc. (NASDAQ PIRS) opened at 5.39 on Friday. The company has a 50-day moving average of $5.38 and a 200 day moving average of $3.93. Pieris Pharmaceuticals, Inc. has a 12 month low of $1.30 and a 12 month high of $5.48. The company’s market cap is $238.82 million.

ILLEGAL ACTIVITY WARNING: “State of Wisconsin Investment Board Purchases New Stake in Pieris Pharmaceuticals, Inc. (PIRS)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/17/state-of-wisconsin-investment-board-purchases-new-stake-in-pieris-pharmaceuticals-inc-pirs.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS).

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.